Field | Sense | Antisense |
siRNA chemical modification | 2-Fluoro* Cholesterol | 2-Fluoro* Cholesterol |
siRNA modification types | 2 | 2 |
Overall number of modifications | 11 | 11 |
Position of modifications | 4,5,19,20 * 1,2,3,17,18,19,20 | 1,2,3,4,5 * 4,5,6,18,19,20 |
Modification on sugar or base or phosphate | Sugar; Phosphate | Sugar; Phosphate |
SMILES (Click to view structure & nomenclature) |
OCC1OCC(F)C1O CC(C)CCCC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C |
OCC1OCC(F)C1O CC(C)CCCC(C)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C |
siRNA Sequence | CGAUGUGUCUAUUGAAGAUUC | CGGCUACACAGAUAACUUCUA |
siRNA length base-pair | 21 | 21 |
siRNA name in paper | R1 | R1 |
Biological activity | NA | |
Experiment used to check activity | Northern Blot | |
Melting temperature (oC) | NA | |
Target gene | Human SOD1 gene | |
siRNA concentration | 20 nM | |
Cell or Organism used | HEK293 cells | |
Transfection method | Lipofectamine 2000 | |
Duration after transfection | 25 Hours | |
Article title | Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates |
|
Reference | 18367449 |